Tonsillectomy, high dose immunoglobulins, and cyclophosphamide in progressive IgA-nephropathy

Acta Oto-Laryngologica, Supplement

Volumn 124, Issue 555, 2004, Pages 32-37

  Rasche, Franz Maximilian ^a   Sailer, Leif Conradin ^a   Czock, David ^a   Keller, Frieder ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cyclophosphamide; High dose; IgA nephropathy; Immunoglobulins; Immunosuppressive therapy; Renal disease progression; Tonsillectomy

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; MALE; MYCOPLASMA PNEUMONIA; NAUSEA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SURVIVAL; TONSILLECTOMY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; ARTICLE; MIDDLE AGED;

CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TONSILLECTOMY;

EID: 11144260164     PISSN: 03655237     EISSN: None     Source Type: Journal    
DOI: 10.1080/03655230410003305     Document Type: Conference Paper

References (29)

1. Ibels LS, Gyory AZ, Caterson RJ, Pollock CA, Mahony JF, Waugh DA, et al. Recognition and management of IgA nephropathy. Drugs 1998; 55: 73-83.
2. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997; 29: 526-32.
3. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-83.
4. Hiki Y, Iwase H, Saitoh M, Saitoh Y, Horii A, Hotta K, et al. Reactivity of glomerular and serum IgA1 to jacalin in IgA nephropathy. Nephron 1996; 72: 429-35.
5. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8.
6. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippen C, Deforges L, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med 1994; 120: 476-84.
7. Faedda R, Pirisi M, Satta A, Bosincu L, Bartoli E. Immunosuppressive treatment of Berger's disease. Clin Pharmacol Ther 1996; 60: 561-7.
8. Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15: 833-5.
9. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-8.
10. Rasche FM, Klotz CH, Czock D, Karges W, Muche R, Jehle PM, et al. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003; 93: c131-6.
11. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996; 72: 237-42.
12. Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study. Am J Kidney Dis 1995; 26: 792-6.
13. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-80.
14. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-7.
15. Tamura S, Ueki K, Ideura H, Tsukada Y, Maezawa A, Kawai H, et al. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 2001; 55: 192-5.
16. Masuda Y, Terazawa K, Kawakami S, Ogura Y, Sugiyama N. Clinical and immunological study of IgA nephropathy before and after tonsillectomy. Acta Otolaryngol 1988; Suppl.454: 248-55.
17. Masuda Y, Tamura S, Sugiyama N. The effect of tonsillectomy and its postoperative clinical course in IgA nephropathy with chronic tonsillitis. Adv Otorhinolaryngol 1992; 47: 203-7.
18. Iino Y, Ambe K, Kato Y, Nakai A, Toriyama M, Saima K, et al. Chronic tonsillitis and IgA nephropathy. Clinical study of patients with and without tonsillectomy. Acta Otolaryngol 1993; Suppl.508: 29-35.
19. Akagi H, Nishizaki K, Hattori K, Kosaka M, Fukushima K, Doi A, et al. Prognosis of tonsillectomy in patients with IgA nephropathy. Acta Otolaryngol 1999; Suppl.540: 64-6.
20. Sugiyama N, Shimizu J, Nakamura M, Kiriu T, Matsuoka K, Masuda Y. Clinicopathological study of the effectiveness of tonsillectomy in IgA nephropathy accompanied by chronic tonsillitis. Acta Otolaryngol 1993; Suppl.508: 43-8.
21. Tamura S, Masuda Y, Inokuchi I, Terasavva K, Sugiyama N. Effect of and indication for tonsillectomy in IgA nephropathy. Acta Otolaryngol 1993; Suppl.508: 23-8.
22. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001; 38: 736-43.
23. Bene MC, Hurault DL, Kessler M, Foliguet B, Faure GC. Tonsils in IgA nephropathy. Contrib Nephrol 1993; 104: 153-61.
24. Furuta T, Hotta O, Horigome I, Chiba S, Noshiro H, Miyazaki M, et al. Steroid pulse therapy combined with tonsillectomy in IgA nephropathy associated with diabetes mellitus. Nephron 2001; 89: 398-401.
25. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51: 147-52.
26. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-7.
27. Scholl U, Wastl U, Risler T, Braun N, Grabensee B, Heering P, et al. The "point of no return" and the rate of progression in the natural history of IgA nephritis. Clin Nephrol 1999; 52: 285-92.
28. Walser M. Progression of chronic renal failure in man. Kidney Int 1990; 37: 1195-210.
29. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80.